Company Overview and News

 
Natus Medical Files Definitive Proxy Materials

2018-05-18 globenewswire
Mails Letter to Shareholders Highlighting Proven Record of Value Creation and Right Plan to Deliver Continued Growth

 
Community Health Systems, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-02 seekingalpha
The following slide deck was published by Community Health Systems, Inc. in conjunction with their 2018 Q1 earnings call.

 
Community Health (CYH) Posts Earnings in Q1, Revenues Top

2018-05-02 zacks
Community Health Systems, Inc. (CYH - Free Report) delivered adjusted income of 13 cents per share in the first quarter of 2018, faring better than the Zacks Consensus Estimate of a loss of 26 cents. The bottom line surged nearly 86% year over year.

 
BRIEF-Community Health Systems Announces Proposed Exchange Offers

2018-05-02 reuters
* COMMUNITY HEALTH SYSTEMS - TO COMMENCE OFFERS TO EXCHANGE UPTO $1,925 MILLION PRINCIPAL AMOUNT OF NEW 9.875% JUNIOR-PRIORITY SECURED NOTES DUE 2023

 
Community Health posts smaller quarterly loss

2018-05-01 reuters
May 1 (Reuters) - Hospital operator Community Health Systems Inc reported a smaller quarterly loss on Tuesday, helped by lower costs.

 
Encompass Health stock price target raised to $68 from $62 at Mizuho

2018-04-27 marketwatch
Rice Hall James & Associates, Llc Buys Encompass Health Corp, Strayer Education Inc, Wix.com, Sells Nektar Therapeutics Inc, Buffalo Wild Wings Inc, Snyder's-Lance Inc

 
Lazard Ltd Reports First-Quarter 2018 Results

2018-04-26 businesswire
“Our clients and our shareholders are benefitting from investments we’ve made in the business, and we continue to pursue opportunities for growth.”

 
Community Health Systems To Broadcast First Quarter 2018 Conference Call Live On The Internet

2018-04-17 globenewswire
FRANKLIN, Tenn., April 17, 2018 (GLOBE NEWSWIRE) -- Community Health Systems, Inc. (NYSE:CYH) today announced that it will provide an online Web simulcast and rebroadcast of its first quarter 2018 conference call.

3
8 Best Cheap Stocks to Buy Now Under $10

2018-04-10 investorplace
The best cheap stocks to buy now are never sure things. There are many stocks under $10 right now that deserve to be there, and will only get cheaper.

1
Quorum Health: Disconnect Between Challenged Fundamentals And Lofty Valuation

2018-03-29 seekingalpha
It does not generate positive cash flow; unless QHC de-levers, cash flow will not occur as LIBOR-based variable rate debt becomes increasingly problematic.

 
Quorum Health: Disconnect Between Challenged Fundamentals & Lofty Valuation

2018-03-29 seekingalpha
It does not generate positive cash flow; unless QHC de-levers, cash flow will not occur as LIBOR-based variable rate debt becomes increasingly problematic.

 
The 7 Most Undervalued Stocks In Larry Robbins’ Portfolio

2018-03-28 investorplace
Larry Robbins is a hedge fund manager and CEO of Glenview Capital Management. He is also well known for his quarterly letters to investors.

1
Implied Volatility Surging for Community Health (CYH) Stock Options

2018-03-27 zacks
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 15, 2018 $10 Put had some of the highest implied volatility of all equity options today.

1
Community Health Systems: Should Bondholders Be Wary?

2018-03-26 seekingalpha
Community Health Systems' (CYH) recent announcement that they were tapping Lazard to help manage their debt situation created some concern for equity and debt holders. Prices for the company’s unsecured 2019 maturities sank to 89 cents on the dollar. Combined with an 8% coupon, the bond’s yield to maturity is quickly approaching 16%. To determine bondholder risk, we need to examine the company’s financial results combined with 2018 guidance and asset sale expectations to see if the worry is overrated.

 
Why did Community Health Stock Sink More Than 50% in a Year?

2018-03-21 zacks
Community Health Systems, Inc. (CYH - Free Report) has been losing out on investors’ confidence due to the stock’s persistently poor performance in comparison to the industry as well as its peers. The company’s lower-than-expected volumes, payer rates, increased bad debt, a weak top line combined with higher operating expenses leading to a further drag in the margin have likely caused this underperformance.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...